The development and distribution of vaccines have been making headlines amid a surge in COVID-19 cases and this past week was no exception.
Novavax Inc. (NVAX), which was up 74%, was one of the top gainers for the week ending January 29, 2021, thanks to encouraging trial results of its COVID-19 vaccine candidate. In a phase III trial, conducted in UK, the two-dose regimen of Novavax vaccine NVX-CoV2373 has been found to have an efficacy rate of 89.3%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.